MBFT, Smithfield to collaborate on swine vaccine development

Collaboration seeks to develop effective gene-based, T-cell directed vaccines for economically significant swine diseases.

 

National Hog Farmer 

Jan 13, 2020

 

MBF Therapeutics Inc. (MBFT), a developer of DNA-based immunotherapeutic checkpoint inhibitor vaccines for the animal health market, announced Jan. 10 that it has signed an agreement with Smithfield Foods Inc. to collaborate on the design and development of swine vaccines based on MBFT's proprietary vaccine platform and delivery system technology.

 

According to MBFT, its "gene-based, T-cell directed vaccine platform and novel calcium phosphate delivery system (i.e., a nonviral adjuvant) will be used to create more effective swine vaccines that produce a robust and durable immune response. By eliciting responses in both T-cells and B-cells, these new and more effective swine vaccines will have the potential to reduce the use of antibiotics, chronic disease and endemic viral reservoirs in pork production."

 

MBFT chief executive officer Thomas Tillett said the development of a more effective vaccine for porcine reproductive and respiratory syndrome (PRRS) using MBFT’s calcium phosphate nanoparticle delivery will be the first phase of the collaborative project between MBFT and Smithfield.

 

Although several inactivated, attenuated vaccines for PRRS are on the market, all of them underperform, MBFT said in its announcement.

 

The second phase of the collaborative project will address the long-term need for better protective immunity to economically significant porcine viral infections through the development of next-generation DNA vaccines, MBFT said.

 

“Whether it is taking PRRS protection to the next level, addressing the need for a cross-protective swine influenza vaccine or applying a gene-based immunomodulator approach to solving the urgent need for a safe, cross-protective and durable African swine fever vaccine, MBFT technology offers an innovative approach to vaccine design that is well suited for use in livestock,” Tillett said...

 

more

https://www.nationalhogfarmer.com/livestock/mbft-smithfield-collaborate-swine-vaccine-development